Plasma homocysteine and lipoprotein profile in patients with peripheral arterial occlusive disease

Angiology

Volumn 51, Issue 3, 2000, Pages 189-196

  Rassoul, Fausi ^a   Richter, Volker ^a   Janke, Christian ^a   Purschwitz, Kathrin ^a   Klötzer, Bernd ^a   Geisel, Jürgen ^b   Herrmann, Wolfgang ^b  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b SAARLAND UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); APOLIPOPROTEIN A1; APOLIPOPROTEIN B; CHOLESTEROL; CYANOCOBALAMIN; FOLIC ACID; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; LIPOPROTEIN; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PYRIDOXINE; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; DYSLIPIDEMIA; GENE MUTATION; HOMOZYGOSITY; HUMAN; HYPERHOMOCYSTEINEMIA; MAJOR CLINICAL STUDY; MALE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; RISK FACTOR;

EID: 0034018386     PISSN: 00033197     EISSN: None     Source Type: Journal    
DOI: 10.1177/000331970005100302     Document Type: Article

References (28)

1. Kang SS, Wong PWK, Becker N: Protein-bound homocyst(e)ine in normal subjects and in patients with homocysteinuria. Pediatr Res 13:1141-1143, 1979.
2. Wu LL, Wu J, Hunt SC, et al: Plasma homocysteine as risk factor for early familial coronary artery disease. Clin Chem 40:552-561, 1994.
3. McCully KS: Homocysteine theory of arteriosclerosis: Development and current status. In: Atherosclerosis Reviews, ed. by Gotto A, Paoletti R. New York: Raven Press, Volume II, 1993, pp 157-246.
4. Schmitz C, Lindpaintner K, Verhoef P, et al: Genetic plymorphism of methylenetetrahydrofolate reductase and myocardial infarction. Circulation 94:1812-1814, 1996.
5. Kluijtmans LAL, van den Heuvel LPWJ, Boers BHJ, et al: Molecular genetic analysis in mild hyperhomocysteinemia: A common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease. Am J Hum Genet 58:35-41, 1996.
6. Simon J, Racek J, Rosolovla H: Homocysteine, a less well-known risk factor in cardiac and vascular disease. Cas lek Cesk 135:263-265, 1996.
7. 6 and folate nutritional status in men with hyperhomocysteinemia. Am J Clin Nutr 57:47-53, 1993.
8. Motulsky AG: Nutritional ecogenetic: Homocysteine-related arteriosclerotic vascular disease, neural tube defects and folic acid. Am J Hum Genet 58:17-20, 1996.
9. den Heijer M, Koster T, Blom HJ, et al: Hyperhomocysteinemia a risk factor for deep-vein thrombosis. N Engl J Med 334:759-762, 1996.
10. Nygård O, Nordrehang JE, Refsum H, et al: Plasma homocysteine levels and mortality; homocysteine levels and coronary artery disease. N Engl J Med 337:230-236, 1997.
11. Robinson K, Mayer EL, Miller DP, et al: Hyperhomocysteinemia and low pyridoxal phosphate: Common and independent reversible risk factors for coronary artery disease. Circulation 92:2825-2830, 1995.
12. Verhoef P, Hennekens CH, Malinow MR, et al: A prospective study of plasma homocysteine and risk of ischemic stroke. Stroke 25:1924-1930, 1994.
13. Fontaine R, Kim M, Kieny R: die chirurgische Behandlung der peripheren Durchblutungsstörungen. Helv chir Acta 5/6:499-533, 1954.
14. Cachovan M: Functional evaluation of intermittent claudication. VASA 26:185-189, 1997.
15. 6 nutritional status. J Chromatography 342:277-284, 1985.
16. Frosst P, Blom HJ, Milos R, et al: A candidate genetic risk factor for vascular disease: A common mutation in methylenetetrahydrofolate reductase. Nature Genet 10:110-114, 1995.
17. Stamler JS, Silvka A: Biological chemistry of thiols in the vasculature and in vasculature-related disease. Nutr Rev 54:1-30, 1996.
18. Dudman NPB, Hale SET, FuW, et al: Homocysteine may contribute to occlusive vascular disease by enhancing leukocyte-endothelial adhesion. Atherosclerosis 134:255, 1997.
19. Naruszewicz M, Klinke M, Bukowska H, et al: Elevated homocysteine increases ability of human aortic cells to oxidise LDL. Atherosclerosis 134:13-14, 1997.
20. Brattström L, Israelsson B, Norrving B, et al: Impaired homocysteine metabolism in early-onset cerebral and peripheral arterial occlusive disease. Atherosclerosis 81:51-60, 1990.
21. Malinow MR, Kang SS, Taglor LM, et al: Prevalence of hyperhomocyst(e)inemia in patients with peripheral arterial occlusive disease. Circulation 79:1180-1188, 1989.
22. Graham IM, Daly LE, Refsum HM, et al: Plasma homocysteine as risk factor for vascular disease. JAMA 277:1775-1781, 1997.
23. Selhub J, Jacques PF, Bostom AG, et al: Association between plasma und homocysteine concentrations and extracranial carotid-artery stenosis. N Engl J Med 332:286-291, 1995.
24. Selhub J, Jacques PF, Bostom AG, et al: Relationship between plasma homocysteine, vitamin status and extracranial carotid-artery stenosis in the Framingham study propulation. J Nutr 126:1258S-1265S, 1996.
25. Verhoef P, Stampfer MJ, Rimm EB: Folate and coronary heart disease. Lipidology 9:17-22, 1998.
26. Alaupovic P: The lipoprotein family concept and its clinical significance. Nutr Metab Cardiovasc Dis 2:52-54, 1992.
27. Fruchart JC, Ailhaud G: Apolipoprotein A-containing lipoprotein particles: Physiological role, quantification, and clinical significance. Clin Chem 38:793-973, 1992.
28. David JS, Reichle RM, Reichle FA: Altered low density lipoproteins in peripheral vascular disease patients. J Surg Res 41:538-542, 1996.